Obesity may sound simple but it’s a much more complex and bizarre disease. Obesity is a complex disease involving an excessive amount of body fat.
In recent decades experts noticed a high number of cases of obesity. More than 40 percent of American adults come under this category. And the major problem it is tremendously hard to treat.
To avoid obesity, one has to opt for continuous lifestyle changes which include healthy eating and exercise. The only two possible options that help are weight loss medicines and bariatric surgery.
But these options carrier a great risk and complications. As we know drugs do not always work and have their own side effects too.
Although lately, scientists have tested an experimental treatment that may open a new door for the treatment of weight loss medicates for obese patients.
In a study, the scientist studied 2000 obese adults from 16 different countries. In the study participates have to take weekly doses of Semalgutide drug which is an existing drug and has already used in the treatment of type 2 diabetes.
A control group took only one placebo in place of the drug. Both groups received a lifestyle mediation course designed to stimulate weight loss.
At the end of the experiment, obese patients who took a placebo lost only a small and clinically nil amount of weight. But patients who took weekly doses of Semalgutide drug showed noticeable effects.
After 68 weeks of treatment, the participants who took semaglutide drug lost an average of 14.9 percent of their body weight and more than 30 percent of the group lost more than 20 percent of their body weight.
This shows that the drug is twice as effective as the existing medication in the market for weight loss.
“No other drug has been discontinued to create this level of weight loss – it’s really a game-changer,” says Obesity researcher Rachel Batterham from University College London.
“For the first time, people can get through drugs that were possible only through weight loss surgery.”
Other than noticeable weight loss participants showed improvement in other areas like a decrease in cardiometabolic risk factors and best quality of life.
While the results are compelling, the semaglutide dose for anti-obesity effects comes with some drawbacks.
But as we know all medications have some side backs too.
Many participants recorded Mild-to-moderate effects of diarrhea and nausea. Although the effects were temporary, this made 60 participants leave the treatment while only five participants of the placebo group left the treatment in between.
At present, only a weekly injection is required for the drug to show its effect. However, the patients preferred the oral form of the drug.
We do not yet have any data regarding what happened to the patients at the end of the trial.
The study was funded by Novo Nordisk, a pharmaceutical company that sells semaglutide as an anti-diabetic drug.
The US FDA, along with its counterparts in the UK and Europe, is currently assessing the data.